Myovant nets $135mm through public offering
Myovant Sciences Inc. (therapies for women's health and prostate cancer) netted $135mm through a public offering of 17.4mm common shares (including the overallotment) at $8.25. Funds will support ongoing Phase III trials with lead candidate relugolix (the LIBERTY trial for uterine fibroids and heavy menstrual bleeding, and the HERO study for advanced prostate cancer), and will also be used to fund potential regulatory filings for the project.
- Antisense, Oligonucleotides
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com